AI drug discovery debate: patents could turn a small lead into a durable moat
a_karvonen · x · 2026-10-08
Karvonen and kuza55 debate monetizing AI-driven drug discovery: patents may convert a small research lead into a durable advantage, but you must patent every way of treating a condition — otherwise the next person with an LLM patents the next-best version and erodes your profits. Karvonen also notes OpenAI and Anthropic have made major investments into bio data, signaling frontier labs are betting on AI drug discovery.
Related event: Researchers Question Whether AI Drug Patents Can Build a Moat(4 posts)→
More from AGI Musings
- Fortnow: AI's real existential threat is taking away our relevance, not killing us — fortnow · 2026-10-08
- Terence Tao on "Math 1.0": how breakthrough proofs ignite fields of follow-up work — rms80 · 2026-10-08
- 'P = NP + AI': The Argument That RL Post-Training Automates All Verifiable Problems — jessi_cata · 2026-10-08
- China Goes 6/6 Gold at IMO Again, Yet Will Never Beat Romania on a Per-Capita Basis — teortaxesTex · 2026-10-08
- The New AI Slop Is Calling Everything AI Slop — rmn_pub · 2026-10-08
- Now anyone can build anything, and almost nobody knows what they want — Paimaamu · 2026-10-08